Track Myomo, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Myomo, Inc. MYO · Stock Open Myomo, Inc. in new tab

1.23 USD
EPS
-0.35
P/B
8.50
ROE
-123.76
Beta
1.71
Target Price
4.64 USD
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
EPS-0.35
Book Value0.15
Price to Book8.50
Debt/Equity344.47
% Insiders10.435%
Growth
Revenue Growth0.21%
Estimates
Forward P/E-5.68
Forward EPS-0.22
Target Mean Price4.64

DCF valuation

Model fair value for Myomo, Inc. (MYO)
Result
Sign in to run the valuation for MYO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus Strong buy · mean target 4.64 USD (low 1.70, high 10.50) · as of 12 Nov 2026
Low 1.70
Mean 4.64
High 10.50
Price 1.23
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Myomo, Inc. Logo Myomo, Inc. Analysis (MYO)

United States Health Care Official Website Stock

Is Myomo, Inc. a good investment? Myomo, Inc. (MYO) is currently trading at 1.23 USD. Market analysts have a consensus price target of 4.64 USD. This suggests a potential upside from current levels.

Earnings Schedule: Myomo, Inc. is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -0.22.

Investor FAQ

Does Myomo, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Myomo, Inc.?

Myomo, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -0.35.

Company Profile

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Exchange Ticker
ASE (United States) MYO
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 31, 2020 1:30
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion